Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers

Código QR

Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers

Guardado en:

Detalles Bibliográficos
Autor principal:	Yingyan Yu
Formato:	article
Lenguaje:	EN
Publicado:	China Anti-Cancer Association 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/676103e2d9b549fea31e5a6893d8b918
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Enriqueta Felip, et al.
Publicado: (2021)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Andrew Haydon, et al.
Publicado: (2021)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Ben‐Yuan Jiang, et al.
Publicado: (2021)

Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
por: Anne R Bass, et al.
Publicado: (2021)

68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
por: Joe-Elie Salem, et al.
Publicado: (2021)

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis
por: Edward J Spangenthal, et al.
Publicado: (2021)

Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study
por: Ye-Jee Kim, et al.
Publicado: (2021)

Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
por: Feicheng Wang, et al.
Publicado: (2021)

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
por: Tomas G Neilan, et al.
Publicado: (2021)

Correction: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
Publicado: (2021)

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
por: Michael Dougan, et al.
Publicado: (2021)

Correction: TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
Publicado: (2021)

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
por: Paolo Antonio Ascierto, et al.
Publicado: (2021)

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
por: Ke Cheng, et al.
Publicado: (2021)

Correction: Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
Publicado: (2021)

Correction: SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
Publicado: (2021)

Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model
por: Chiao-Fang Teng, et al.
Publicado: (2020)

Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Alice Tzeng, et al.
Publicado: (2021)

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
por: Kun-Hsing Yu, et al.
Publicado: (2021)

Correction notice to “Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model”
por: Chiao-Fang Teng, et al.
Publicado: (2021)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Frank Riemer, et al.
Publicado: (2021)

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
por: Dirk Schadendorf, et al.
Publicado: (2021)

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
por: James Harber, et al.
Publicado: (2021)

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
por: Marco Donia, et al.
Publicado: (2021)

Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Publicado: (2021)

Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
por: Shunichi Taki, et al.
Publicado: (2021)

Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
por: Dobrin Draganov, et al.
Publicado: (2021)

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
por: Guru Sonpavde, et al.
Publicado: (2021)

Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
por: Chisato Ohe, et al.
Publicado: (2021)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Shahram Salek-Ardakani, et al.
Publicado: (2021)

Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
por: Theresa L Walunas, et al.
Publicado: (2021)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Nicola Personeni, et al.
Publicado: (2021)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
por: Giustini N, et al.
Publicado: (2021)

In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
por: In-San Kim, et al.
Publicado: (2021)

Correction: In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
Publicado: (2021)

Progress of Immune Checkpoint Inhibitors  in the Treatment of Advanced Pulmonary Neuroendocrine Tumors
por: Haoqing CHEN, et al.
Publicado: (2021)

Are another 5 years of adjuvant aromatase inhibitor therapy needed?
por: Mo QG, et al.
Publicado: (2016)

Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy
por: Yael Artzy-Randrup, et al.
Publicado: (2021)

Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy
por: Alberto Carmona-Bayonas, et al.
Publicado: (2021)

FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity
por: Simon Timbrell, et al.
Publicado: (2021)